Jeffrey A. Allen

University of Minnesota — United States

Medicine · Health Sciences

37h-index8.2kcitations149works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peripheral Neuropathies and Disorders(65), Hereditary Neurological Disorders(54), Myasthenia Gravis and Thymoma(29), Peripheral Nerve Disorders(20), Entrepreneurship Studies and Influences(10)

Publications146 total

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial
Therapeutic Advances in Neurological Disorders·2026Open Access
Use of Circulating Tumor DNA in Oncology
2025
Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Journal of the Peripheral Nervous System·2025Open Access
ABS0555 SAFETY PROFILE OF SUBCUTANEOUS EFGARTIGIMOD PH20 FROM CLINICAL TRIALS IN MYASTHENIA GRAVIS AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Annals of the Rheumatic Diseases·2025Open Access
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases
Expert Review of Clinical Immunology·2025· 7 cited
Real-world Characteristics and Disease Management for a Virtual Longitudinal Cohort of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (P10-11.034)
Neurology·2025
Phase 3 Trial Designs Evaluating Riliprubart, a C1s-Complement Inhibitor, in Chronic Inflammatory Demyelinating Polyneuropathy (P10-11.027)
Neurology·2025· 2 cited
Timed Up-and-Go (TUG) Test in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (P11-11.001)
Neurology·2025
Long-Term Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Interim Results from the ADHERE+ Study (S16.002)
Neurology·2025
A Statistical Model to Facilitate Differentiation of Chronic Inflammatory Demyelinating Polyneuropathy Versus Mimics (S16.010)
Neurology·2025
Treatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE Study (P10-11.025)
Neurology·2025
Feasibility and Reliability of a Monitoring App for Chronic Inflammatory Neuropathies
Journal of the Peripheral Nervous System·2025Open Access
Efficacy and safety of efgartigimod PH20 subcutaneously (sc) in chronic inflammatory demyelinating polyneuropathy (CIDP): results from the ADHERE/ADHERE+ studies
Nervenheilkunde·2025
Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling
Journal of the Peripheral Nervous System·2025· 5 cited
Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy
BMC Neurology·2024· 1 citedOpen Access
Efficacy and Safety of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: Results of ADHERE/ADHERE+
Neurology·2024Open Access
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
The Lancet Neurology·2024· 67 citedOpen Access
New chronic inflammatory demyelinating polyneuropathy/Guillain–Barré syndrome guidelines – impact on clinical practise
Current Opinion in Neurology·2024· 2 cited
Examining hydrogen peroxide-containing organelles in seaweeds
PubMed·2024Open Access
Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Results from the ADHERE Trial (PL5.002)
Neurology·2024· 6 cited
page 1 of 8Next →

Frequent Co-authors

Michael H. Morris(11), Richard A. Lewis(9), Minet Schindehutte(6), Luís Querol(5), Pieter A. van Doorn(4), Senda Ajroud‐Driss(4), Ramon A. Avila(3), Robert D. M. Hadden(3), Filip Eftimov(3), Satoshi Kuwabara(3), Robert Sufit(3), Peter Van den Bergh(2), Bert Avau(2), Patrik Vankrunkelsven(2), Shahram Attarian(2), Patricia H. Blomkwist‐Markens(2), David R. Cornblath(2), H. Stephan Goedee(2), Thomas Harbo(2), Michael P. Lunn(2)